This Neo-PLANET study provided evidence for the combination of anti-PD-1 antibody camrelizumab and concurrent chemoradiotherapy as neoadjuvant therapy for locally advanced gastric adenocarcinoma, which resulted in a pCR rate of 33.3% (95% CI, 18.6–51.0), MPR rate of 44.4% (95% CI, 27.9–61.9), and R0 resection rate of 91.7% in 36 patients with resectable T3-4N + M0 adenocarcinoma of stomach or GEJ. Here, PDCD1 is linked to gastric adenocarcinoma.